2020 Clinical Trials DEA Policy 
NORML
APRIL 8, 2020
Under existing regulations, the agency only licenses one facility — the University of Mississippi — to cultivate cannabis for use in FDA-approved clinical trials. In 2016, the agency appeared to reconsider its longstanding policy, and publicly stated for the first time that it would consider additional applicants.
The Cannigma
JUNE 14, 2021
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
MAY 7, 2020
Ole Miss got the cannabis study and research cultivation gig from the DEA (via a contract with the National Institute on Drug Abuse (NIDA)) in 1968. for various studies, including FDA-approved clinical trials. In 2016, the DEA finally shifted to different treatment around expanded research efforts into cannabis beyond Ole Miss.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Cannabis Law Report
OCTOBER 4, 2021
A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Oregon’s Psilocybin Services Act (“PSA”), adopted via initiative in November 2020, makes therapeutic use of psilocybin legal under Oregon state law. Source: [link].
SpeedWeed
MARCH 28, 2021
CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? Seventy-six mostly male veterans between the ages of 24 and 77 completed the Phase 1 trial. Co-author Dr Sue Sisley says that the results are promising.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,
Expert insights. Personalized for you.
352 
Let's personalize your content